新型烷化剂替莫唑胺治疗胶质母细胞瘤的研究  

A clinical effect of new-type alkylating antineoplastics temozolomide in patients with glioblastoma

作　　者：李学[1] 王增光[2] 杨卫东[2] 杨学军[2] 杨树源[2] 张建宁[2] 岳树源[2] 

机构地区：[1]天津市汉沽区医院神经外科,天津300480 [2]天津医科大学总医院神经外科,天津300052

出　　处：《中国保健》2010年第2期11-13,共3页

摘　　要：目的研究新型烷化剂类抗肿瘤药一替莫唑胺（TMZ）对胶质母细胞瘤化疗的有效性和安全性。方法选择2005年1月至2008年1月收治的经病理学证实的胶质母细胞瘤患者70例，随机分成两组，按体表面积分别给以替莫唑胺和司莫司汀（CCNU）化疗2～6个疗程。每疗程进行临床随访、定期复查强化cT或MRI，分别进行未进展存活率、实体肿瘤客观疗效、患者生活质量和药物安全性的评定。结果TMZ组患者未进展存活率较CCNU组明显提高，差异具有统计学意义（P〈0．01）；影像所示的TMZ组的实体肿瘤完全缓解率为22．85％，而CCNU组为8．57％（P〈0．01）；TMZ组患者生活质量的改善情况优于CCNU组，而不良事件的发生率低于CCNU组。结论替莫唑胺能明显延长胶质母细胞瘤患者未进展存活时间，有效抑制胶质母细胞瘤的生长，客观缓解率高，耐受性良好且安全性较高。Objective To study the efficacy and security of new-type alkylating antineoplastics temozolomide （TMZ） in patients with glioblastoma. Methods From January, 2005 to January, 2008, 70 patients, certified to have glioblastoma by pathology, were randomly divided into two groups. TMZ or Semustine （CCNU） was administered respectively according to body surface area, and 2-6 treatment courses were performed in these cases Meantime, clinical experience and contrast-enhanced CT or GD-MRI scan should be performed every course. The progression free survival （PFS） , image based tumor response, quality of life, and security were evaluated respectively. Results The progression free survival rates of patients in TMZ group were higher than that in CCNU group with significant difference （P〈0.05）. Image based tumor compelte response rates were 22.85% in TMZ group and 8.57% in CCNU group （P〈0.05）. Patients with TMZ treatment experienced better quality of life and fewer adverse drug events than those with CCNU treatment. Conclusion TMZ can evidently prolong the progression free survival time of patients by limiting aggressive growth of glioblastoma effectively . TMZ showed more efficient tumor response rate with good tolerability and safety compared with CCNU.

关 键 词：烷化剂 替莫唑胺 司莫司汀 胶质母细胞瘤 

分 类 号：R739.4[医药卫生—肿瘤;医药卫生—临床医学]